nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—GNRHR—GPCRs, Other—HRH4—stomach cancer	0.00643	0.0533	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—KISS1R—stomach cancer	0.005	0.0414	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1R—stomach cancer	0.00447	0.037	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—AGTR2—stomach cancer	0.0044	0.0365	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—F2R—stomach cancer	0.00369	0.0306	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.00331	0.0274	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—KISS1—stomach cancer	0.00322	0.0267	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—stomach cancer	0.00288	0.0239	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GAST—stomach cancer	0.00277	0.0229	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—RGS2—stomach cancer	0.00277	0.0229	CbGpPWpGaD
Degarelix—GNRHR—GPCRs, Other—ADRB2—stomach cancer	0.00272	0.0226	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—KISS1R—stomach cancer	0.00252	0.0209	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RGS2—stomach cancer	0.00248	0.0205	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—stomach cancer	0.00248	0.0205	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.00239	0.0198	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.00213	0.0177	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—F2R—stomach cancer	0.00207	0.0172	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—ANXA1—stomach cancer	0.00195	0.0162	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—stomach cancer	0.00186	0.0154	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—HRH4—stomach cancer	0.00182	0.0151	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—stomach cancer	0.00174	0.0145	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—KISS1—stomach cancer	0.00162	0.0135	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—stomach cancer	0.00148	0.0123	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—KISS1R—stomach cancer	0.00142	0.0118	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	0.00139	0.0115	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	0.00137	0.0114	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	0.00134	0.0111	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KISS1R—stomach cancer	0.00129	0.0107	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	0.00129	0.0107	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	0.00125	0.0104	CbGpPWpGaD
Degarelix—Hepatobiliary disease—Methotrexate—stomach cancer	0.00112	0.00127	CcSEcCtD
Degarelix—Hypersensitivity—Irinotecan—stomach cancer	0.00111	0.00126	CcSEcCtD
Degarelix—Hypertension—Docetaxel—stomach cancer	0.0011	0.00126	CcSEcCtD
Degarelix—Palpitations—Capecitabine—stomach cancer	0.00109	0.00124	CcSEcCtD
Degarelix—Arthralgia—Docetaxel—stomach cancer	0.00109	0.00124	CcSEcCtD
Degarelix—Renal failure—Epirubicin—stomach cancer	0.00108	0.00123	CcSEcCtD
Degarelix—Asthenia—Irinotecan—stomach cancer	0.00108	0.00123	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.00108	0.00123	CcSEcCtD
Degarelix—Urinary tract infection—Epirubicin—stomach cancer	0.00107	0.00122	CcSEcCtD
Degarelix—Dysuria—Doxorubicin—stomach cancer	0.00107	0.00122	CcSEcCtD
Degarelix—Hypertension—Capecitabine—stomach cancer	0.00107	0.00122	CcSEcCtD
Degarelix—Hypersensitivity—Fluorouracil—stomach cancer	0.00107	0.00121	CcSEcCtD
Degarelix—Dry mouth—Docetaxel—stomach cancer	0.00106	0.00121	CcSEcCtD
Degarelix—Pollakiuria—Doxorubicin—stomach cancer	0.00106	0.0012	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—AGTR2—stomach cancer	0.00106	0.00877	CbGpPWpGaD
Degarelix—Arthralgia—Capecitabine—stomach cancer	0.00105	0.0012	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.00105	0.00119	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—F2R—stomach cancer	0.00105	0.00867	CbGpPWpGaD
Degarelix—Urinary tract disorder—Methotrexate—stomach cancer	0.00105	0.00119	CcSEcCtD
Degarelix—Hepatobiliary disease—Epirubicin—stomach cancer	0.00104	0.00119	CcSEcCtD
Degarelix—Anaphylactic shock—Docetaxel—stomach cancer	0.00104	0.00119	CcSEcCtD
Degarelix—Weight increased—Doxorubicin—stomach cancer	0.00104	0.00119	CcSEcCtD
Degarelix—Discomfort—Capecitabine—stomach cancer	0.00104	0.00118	CcSEcCtD
Degarelix—Urethral disorder—Methotrexate—stomach cancer	0.00104	0.00118	CcSEcCtD
Degarelix—Weight decreased—Doxorubicin—stomach cancer	0.00104	0.00118	CcSEcCtD
Degarelix—Hyperglycaemia—Doxorubicin—stomach cancer	0.00103	0.00117	CcSEcCtD
Degarelix—Diarrhoea—Irinotecan—stomach cancer	0.00103	0.00117	CcSEcCtD
Degarelix—Dry mouth—Capecitabine—stomach cancer	0.00103	0.00117	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—HRH4—stomach cancer	0.00103	0.00853	CbGpPWpGaD
Degarelix—Nervous system disorder—Docetaxel—stomach cancer	0.00102	0.00116	CcSEcCtD
Degarelix—Pruritus—Fluorouracil—stomach cancer	0.00102	0.00116	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—HTR1A—stomach cancer	0.00102	0.00844	CbGpPWpGaD
Degarelix—Skin disorder—Docetaxel—stomach cancer	0.00101	0.00115	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	0.00101	0.0084	CbGpPWpGaD
Degarelix—Renal failure—Doxorubicin—stomach cancer	0.001	0.00114	CcSEcCtD
Degarelix—Dizziness—Irinotecan—stomach cancer	0.000998	0.00114	CcSEcCtD
Degarelix—Urinary tract infection—Doxorubicin—stomach cancer	0.000993	0.00113	CcSEcCtD
Degarelix—Nervous system disorder—Capecitabine—stomach cancer	0.000991	0.00113	CcSEcCtD
Degarelix—Eye disorder—Methotrexate—stomach cancer	0.000989	0.00113	CcSEcCtD
Degarelix—Diarrhoea—Fluorouracil—stomach cancer	0.000989	0.00113	CcSEcCtD
Degarelix—Hypoaesthesia—Epirubicin—stomach cancer	0.000986	0.00112	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—ANXA1—stomach cancer	0.000984	0.00815	CbGpPWpGaD
Degarelix—Cardiac disorder—Methotrexate—stomach cancer	0.000983	0.00112	CcSEcCtD
Degarelix—Skin disorder—Capecitabine—stomach cancer	0.000981	0.00112	CcSEcCtD
Degarelix—Urinary tract disorder—Epirubicin—stomach cancer	0.000978	0.00111	CcSEcCtD
Degarelix—Hyperhidrosis—Capecitabine—stomach cancer	0.000977	0.00111	CcSEcCtD
Degarelix—Oedema peripheral—Epirubicin—stomach cancer	0.000976	0.00111	CcSEcCtD
Degarelix—Hypotension—Docetaxel—stomach cancer	0.000975	0.00111	CcSEcCtD
Degarelix—Urethral disorder—Epirubicin—stomach cancer	0.000971	0.0011	CcSEcCtD
Degarelix—Hepatobiliary disease—Doxorubicin—stomach cancer	0.000966	0.0011	CcSEcCtD
Degarelix—Angiopathy—Methotrexate—stomach cancer	0.000961	0.00109	CcSEcCtD
Degarelix—Vomiting—Irinotecan—stomach cancer	0.00096	0.00109	CcSEcCtD
Degarelix—Immune system disorder—Methotrexate—stomach cancer	0.000956	0.00109	CcSEcCtD
Degarelix—Dizziness—Fluorouracil—stomach cancer	0.000956	0.00109	CcSEcCtD
Degarelix—Mediastinal disorder—Methotrexate—stomach cancer	0.000954	0.00109	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—ADRB1—stomach cancer	0.000953	0.0079	CbGpPWpGaD
Degarelix—Rash—Irinotecan—stomach cancer	0.000952	0.00108	CcSEcCtD
Degarelix—Dermatitis—Irinotecan—stomach cancer	0.000951	0.00108	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000951	0.00108	CcSEcCtD
Degarelix—Chills—Methotrexate—stomach cancer	0.00095	0.00108	CcSEcCtD
Degarelix—Headache—Irinotecan—stomach cancer	0.000946	0.00108	CcSEcCtD
Degarelix—Hypotension—Capecitabine—stomach cancer	0.000944	0.00107	CcSEcCtD
Degarelix—Insomnia—Docetaxel—stomach cancer	0.000944	0.00107	CcSEcCtD
Degarelix—Alopecia—Methotrexate—stomach cancer	0.000936	0.00106	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—HRH4—stomach cancer	0.000935	0.00775	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—stomach cancer	0.000934	0.00775	CbGpPWpGaD
Degarelix—Dyspnoea—Docetaxel—stomach cancer	0.00093	0.00106	CcSEcCtD
Degarelix—Mental disorder—Methotrexate—stomach cancer	0.000928	0.00105	CcSEcCtD
Degarelix—Eye disorder—Epirubicin—stomach cancer	0.000926	0.00105	CcSEcCtD
Degarelix—Erythema—Methotrexate—stomach cancer	0.000922	0.00105	CcSEcCtD
Degarelix—Malnutrition—Methotrexate—stomach cancer	0.000922	0.00105	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000921	0.00105	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—stomach cancer	0.00092	0.00105	CcSEcCtD
Degarelix—Vomiting—Fluorouracil—stomach cancer	0.000919	0.00105	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—KISS1—stomach cancer	0.000917	0.00761	CbGpPWpGaD
Degarelix—Insomnia—Capecitabine—stomach cancer	0.000914	0.00104	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—stomach cancer	0.000912	0.00104	CcSEcCtD
Degarelix—Rash—Fluorouracil—stomach cancer	0.000912	0.00104	CcSEcCtD
Degarelix—Dermatitis—Fluorouracil—stomach cancer	0.000911	0.00104	CcSEcCtD
Degarelix—Decreased appetite—Docetaxel—stomach cancer	0.000907	0.00103	CcSEcCtD
Degarelix—Headache—Fluorouracil—stomach cancer	0.000906	0.00103	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—stomach cancer	0.000905	0.00103	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—stomach cancer	0.000903	0.00103	CcSEcCtD
Degarelix—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000901	0.00102	CcSEcCtD
Degarelix—Dyspnoea—Capecitabine—stomach cancer	0.000901	0.00102	CcSEcCtD
Degarelix—Fatigue—Docetaxel—stomach cancer	0.0009	0.00102	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—stomach cancer	0.000899	0.00102	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—stomach cancer	0.000899	0.00102	CcSEcCtD
Degarelix—Nausea—Irinotecan—stomach cancer	0.000897	0.00102	CcSEcCtD
Degarelix—Immune system disorder—Epirubicin—stomach cancer	0.000895	0.00102	CcSEcCtD
Degarelix—Mediastinal disorder—Epirubicin—stomach cancer	0.000893	0.00102	CcSEcCtD
Degarelix—Constipation—Docetaxel—stomach cancer	0.000892	0.00101	CcSEcCtD
Degarelix—Pain—Docetaxel—stomach cancer	0.000892	0.00101	CcSEcCtD
Degarelix—Back pain—Methotrexate—stomach cancer	0.000891	0.00101	CcSEcCtD
Degarelix—Chills—Epirubicin—stomach cancer	0.000889	0.00101	CcSEcCtD
Degarelix—Arrhythmia—Epirubicin—stomach cancer	0.000885	0.00101	CcSEcCtD
Degarelix—Decreased appetite—Capecitabine—stomach cancer	0.000878	0.000999	CcSEcCtD
Degarelix—Alopecia—Epirubicin—stomach cancer	0.000876	0.000996	CcSEcCtD
Degarelix—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000872	0.000992	CcSEcCtD
Degarelix—Fatigue—Capecitabine—stomach cancer	0.000871	0.000991	CcSEcCtD
Degarelix—Vision blurred—Methotrexate—stomach cancer	0.000869	0.000988	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—stomach cancer	0.000868	0.000987	CcSEcCtD
Degarelix—Pain—Capecitabine—stomach cancer	0.000864	0.000983	CcSEcCtD
Degarelix—Constipation—Capecitabine—stomach cancer	0.000864	0.000983	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—stomach cancer	0.000863	0.000981	CcSEcCtD
Degarelix—Erythema—Epirubicin—stomach cancer	0.000863	0.000981	CcSEcCtD
Degarelix—Feeling abnormal—Docetaxel—stomach cancer	0.00086	0.000978	CcSEcCtD
Degarelix—Nausea—Fluorouracil—stomach cancer	0.000859	0.000977	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—stomach cancer	0.000857	0.000974	CcSEcCtD
Degarelix—Ill-defined disorder—Methotrexate—stomach cancer	0.000855	0.000972	CcSEcCtD
Degarelix—Gastrointestinal pain—Docetaxel—stomach cancer	0.000853	0.00097	CcSEcCtD
Degarelix—Anaemia—Methotrexate—stomach cancer	0.000852	0.000969	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—stomach cancer	0.000851	0.000968	CcSEcCtD
Degarelix—Back pain—Epirubicin—stomach cancer	0.000834	0.000949	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—stomach cancer	0.000834	0.00691	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KISS1—stomach cancer	0.000833	0.00691	CbGpPWpGaD
Degarelix—Feeling abnormal—Capecitabine—stomach cancer	0.000833	0.000947	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—stomach cancer	0.000832	0.000946	CcSEcCtD
Degarelix—Malaise—Methotrexate—stomach cancer	0.000831	0.000945	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—stomach cancer	0.000829	0.000943	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—stomach cancer	0.000828	0.000942	CcSEcCtD
Degarelix—Gastrointestinal pain—Capecitabine—stomach cancer	0.000826	0.00094	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—stomach cancer	0.000826	0.00094	CcSEcCtD
Degarelix—Body temperature increased—Docetaxel—stomach cancer	0.000825	0.000938	CcSEcCtD
Degarelix—Abdominal pain—Docetaxel—stomach cancer	0.000825	0.000938	CcSEcCtD
Degarelix—Chills—Doxorubicin—stomach cancer	0.000823	0.000935	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—stomach cancer	0.000819	0.000931	CcSEcCtD
Degarelix—Vision blurred—Epirubicin—stomach cancer	0.000813	0.000924	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—stomach cancer	0.00081	0.000921	CcSEcCtD
Degarelix—Mental disorder—Doxorubicin—stomach cancer	0.000803	0.000913	CcSEcCtD
Degarelix—Urticaria—Capecitabine—stomach cancer	0.000803	0.000913	CcSEcCtD
Degarelix—Ill-defined disorder—Epirubicin—stomach cancer	0.0008	0.00091	CcSEcCtD
Degarelix—Body temperature increased—Capecitabine—stomach cancer	0.000799	0.000908	CcSEcCtD
Degarelix—Abdominal pain—Capecitabine—stomach cancer	0.000799	0.000908	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—stomach cancer	0.000798	0.000908	CcSEcCtD
Degarelix—Erythema—Doxorubicin—stomach cancer	0.000798	0.000908	CcSEcCtD
Degarelix—Anaemia—Epirubicin—stomach cancer	0.000797	0.000907	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—GAST—stomach cancer	0.000789	0.00654	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RGS2—stomach cancer	0.000789	0.00654	CbGpPWpGaD
Degarelix—Arthralgia—Methotrexate—stomach cancer	0.000785	0.000892	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000779	0.000886	CcSEcCtD
Degarelix—Malaise—Epirubicin—stomach cancer	0.000778	0.000884	CcSEcCtD
Degarelix—Discomfort—Methotrexate—stomach cancer	0.000775	0.000882	CcSEcCtD
Degarelix—Back pain—Doxorubicin—stomach cancer	0.000772	0.000878	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—ADRB2—stomach cancer	0.000772	0.0064	CbGpPWpGaD
Degarelix—Hypersensitivity—Docetaxel—stomach cancer	0.000769	0.000874	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—stomach cancer	0.000767	0.000873	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GLI3—stomach cancer	0.000764	0.00633	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KISS1R—stomach cancer	0.000764	0.00633	CbGpPWpGaD
Degarelix—Palpitations—Epirubicin—stomach cancer	0.000762	0.000867	CcSEcCtD
Degarelix—Anaphylactic shock—Methotrexate—stomach cancer	0.000752	0.000855	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—stomach cancer	0.000752	0.000855	CcSEcCtD
Degarelix—Asthenia—Docetaxel—stomach cancer	0.000749	0.000851	CcSEcCtD
Degarelix—Hypertension—Epirubicin—stomach cancer	0.000745	0.000847	CcSEcCtD
Degarelix—Hypersensitivity—Capecitabine—stomach cancer	0.000744	0.000847	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—stomach cancer	0.00074	0.000842	CcSEcCtD
Degarelix—Pruritus—Docetaxel—stomach cancer	0.000738	0.00084	CcSEcCtD
Degarelix—Nervous system disorder—Methotrexate—stomach cancer	0.000738	0.000839	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—stomach cancer	0.000738	0.000839	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—stomach cancer	0.000734	0.000835	CcSEcCtD
Degarelix—Skin disorder—Methotrexate—stomach cancer	0.000731	0.000831	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000729	0.000829	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—RBP1—stomach cancer	0.000729	0.00604	CbGpPWpGaD
Degarelix—Hyperhidrosis—Methotrexate—stomach cancer	0.000727	0.000827	CcSEcCtD
Degarelix—Discomfort—Epirubicin—stomach cancer	0.000725	0.000825	CcSEcCtD
Degarelix—Asthenia—Capecitabine—stomach cancer	0.000725	0.000824	CcSEcCtD
Degarelix—Malaise—Doxorubicin—stomach cancer	0.00072	0.000818	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—stomach cancer	0.000718	0.000817	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—GAST—stomach cancer	0.000716	0.00594	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RGS2—stomach cancer	0.000716	0.00594	CbGpPWpGaD
Degarelix—Pruritus—Capecitabine—stomach cancer	0.000715	0.000813	CcSEcCtD
Degarelix—Diarrhoea—Docetaxel—stomach cancer	0.000714	0.000812	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—stomach cancer	0.000705	0.000802	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—stomach cancer	0.000704	0.0008	CcSEcCtD
Degarelix—Hypotension—Methotrexate—stomach cancer	0.000703	0.000799	CcSEcCtD
Degarelix—Diarrhoea—Capecitabine—stomach cancer	0.000691	0.000786	CcSEcCtD
Degarelix—Nervous system disorder—Epirubicin—stomach cancer	0.00069	0.000785	CcSEcCtD
Degarelix—Dizziness—Docetaxel—stomach cancer	0.00069	0.000785	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—stomach cancer	0.000689	0.000784	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000685	0.000779	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—stomach cancer	0.000684	0.000778	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—stomach cancer	0.00068	0.000774	CcSEcCtD
Degarelix—Insomnia—Methotrexate—stomach cancer	0.00068	0.000774	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—stomach cancer	0.000679	0.000773	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000675	0.000767	CcSEcCtD
Degarelix—Discomfort—Doxorubicin—stomach cancer	0.000671	0.000763	CcSEcCtD
Degarelix—Dyspnoea—Methotrexate—stomach cancer	0.000671	0.000763	CcSEcCtD
Degarelix—Dizziness—Capecitabine—stomach cancer	0.000668	0.00076	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—stomach cancer	0.000664	0.000756	CcSEcCtD
Degarelix—Vomiting—Docetaxel—stomach cancer	0.000664	0.000755	CcSEcCtD
Degarelix—Rash—Docetaxel—stomach cancer	0.000658	0.000748	CcSEcCtD
Degarelix—Hypotension—Epirubicin—stomach cancer	0.000658	0.000748	CcSEcCtD
Degarelix—Dermatitis—Docetaxel—stomach cancer	0.000657	0.000748	CcSEcCtD
Degarelix—Decreased appetite—Methotrexate—stomach cancer	0.000654	0.000744	CcSEcCtD
Degarelix—Headache—Docetaxel—stomach cancer	0.000654	0.000743	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—stomach cancer	0.000651	0.000741	CcSEcCtD
Degarelix—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000649	0.000738	CcSEcCtD
Degarelix—Fatigue—Methotrexate—stomach cancer	0.000649	0.000737	CcSEcCtD
Degarelix—Pain—Methotrexate—stomach cancer	0.000643	0.000731	CcSEcCtD
Degarelix—Vomiting—Capecitabine—stomach cancer	0.000642	0.000731	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000641	0.000729	CcSEcCtD
Degarelix—Nervous system disorder—Doxorubicin—stomach cancer	0.000639	0.000726	CcSEcCtD
Degarelix—Rash—Capecitabine—stomach cancer	0.000637	0.000724	CcSEcCtD
Degarelix—Insomnia—Epirubicin—stomach cancer	0.000637	0.000724	CcSEcCtD
Degarelix—Dermatitis—Capecitabine—stomach cancer	0.000637	0.000724	CcSEcCtD
Degarelix—Headache—Capecitabine—stomach cancer	0.000633	0.00072	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—stomach cancer	0.000633	0.000719	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—stomach cancer	0.00063	0.000716	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—stomach cancer	0.000628	0.000714	CcSEcCtD
Degarelix—Nausea—Docetaxel—stomach cancer	0.00062	0.000705	CcSEcCtD
Degarelix—Feeling abnormal—Methotrexate—stomach cancer	0.00062	0.000705	CcSEcCtD
Degarelix—Gastrointestinal pain—Methotrexate—stomach cancer	0.000615	0.000699	CcSEcCtD
Degarelix—Decreased appetite—Epirubicin—stomach cancer	0.000612	0.000696	CcSEcCtD
Degarelix—Hypotension—Doxorubicin—stomach cancer	0.000609	0.000692	CcSEcCtD
Degarelix—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000608	0.000691	CcSEcCtD
Degarelix—Fatigue—Epirubicin—stomach cancer	0.000607	0.00069	CcSEcCtD
Degarelix—Constipation—Epirubicin—stomach cancer	0.000602	0.000685	CcSEcCtD
Degarelix—Pain—Epirubicin—stomach cancer	0.000602	0.000685	CcSEcCtD
Degarelix—Nausea—Capecitabine—stomach cancer	0.0006	0.000683	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—AGTR2—stomach cancer	0.000598	0.00496	CbGpPWpGaD
Degarelix—Urticaria—Methotrexate—stomach cancer	0.000598	0.00068	CcSEcCtD
Degarelix—Abdominal pain—Methotrexate—stomach cancer	0.000595	0.000676	CcSEcCtD
Degarelix—Body temperature increased—Methotrexate—stomach cancer	0.000595	0.000676	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—WWOX—stomach cancer	0.000594	0.00492	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000593	0.000675	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—F2R—stomach cancer	0.000591	0.0049	CbGpPWpGaD
Degarelix—Insomnia—Doxorubicin—stomach cancer	0.000589	0.00067	CcSEcCtD
Degarelix—Dyspnoea—Doxorubicin—stomach cancer	0.000581	0.00066	CcSEcCtD
Degarelix—Feeling abnormal—Epirubicin—stomach cancer	0.00058	0.00066	CcSEcCtD
Degarelix—Gastrointestinal pain—Epirubicin—stomach cancer	0.000576	0.000655	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—HTR1A—stomach cancer	0.000575	0.00477	CbGpPWpGaD
Degarelix—Decreased appetite—Doxorubicin—stomach cancer	0.000566	0.000644	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000562	0.000639	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—stomach cancer	0.000562	0.000639	CcSEcCtD
Degarelix—Urticaria—Epirubicin—stomach cancer	0.000559	0.000636	CcSEcCtD
Degarelix—Constipation—Doxorubicin—stomach cancer	0.000557	0.000633	CcSEcCtD
Degarelix—Pain—Doxorubicin—stomach cancer	0.000557	0.000633	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—stomach cancer	0.000556	0.000633	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—stomach cancer	0.000556	0.000633	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—ANXA1—stomach cancer	0.000556	0.00461	CbGpPWpGaD
Degarelix—Hypersensitivity—Methotrexate—stomach cancer	0.000554	0.00063	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—WIF1—stomach cancer	0.000552	0.00458	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRH4—stomach cancer	0.000552	0.00458	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AGTR2—stomach cancer	0.000543	0.0045	CbGpPWpGaD
Degarelix—Asthenia—Methotrexate—stomach cancer	0.00054	0.000614	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—ADRB1—stomach cancer	0.000538	0.00446	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—F2R—stomach cancer	0.000537	0.00445	CbGpPWpGaD
Degarelix—Feeling abnormal—Doxorubicin—stomach cancer	0.000537	0.00061	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000533	0.000606	CcSEcCtD
Degarelix—Pruritus—Methotrexate—stomach cancer	0.000532	0.000605	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—HTR1A—stomach cancer	0.000523	0.00433	CbGpPWpGaD
Degarelix—Hypersensitivity—Epirubicin—stomach cancer	0.000519	0.00059	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—stomach cancer	0.000517	0.000588	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—stomach cancer	0.000515	0.000586	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—stomach cancer	0.000515	0.000586	CcSEcCtD
Degarelix—Diarrhoea—Methotrexate—stomach cancer	0.000515	0.000585	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PRKAB1—stomach cancer	0.00051	0.00422	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—stomach cancer	0.000508	0.00421	CbGpPWpGaD
Degarelix—Asthenia—Epirubicin—stomach cancer	0.000505	0.000574	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—ANXA1—stomach cancer	0.000505	0.00418	CbGpPWpGaD
Degarelix—Pruritus—Epirubicin—stomach cancer	0.000498	0.000566	CcSEcCtD
Degarelix—Dizziness—Methotrexate—stomach cancer	0.000497	0.000566	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—KISS1—stomach cancer	0.000492	0.00408	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RNF43—stomach cancer	0.000492	0.00408	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	0.000489	0.00406	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ADRB1—stomach cancer	0.000489	0.00405	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—stomach cancer	0.000483	0.00401	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—stomach cancer	0.000483	0.00401	CbGpPWpGaD
Degarelix—Diarrhoea—Epirubicin—stomach cancer	0.000482	0.000548	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—stomach cancer	0.00048	0.000546	CcSEcCtD
Degarelix—Vomiting—Methotrexate—stomach cancer	0.000478	0.000544	CcSEcCtD
Degarelix—Rash—Methotrexate—stomach cancer	0.000474	0.000539	CcSEcCtD
Degarelix—Dermatitis—Methotrexate—stomach cancer	0.000474	0.000539	CcSEcCtD
Degarelix—Headache—Methotrexate—stomach cancer	0.000471	0.000536	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3CA—stomach cancer	0.000469	0.00389	CbGpPWpGaD
Degarelix—Asthenia—Doxorubicin—stomach cancer	0.000467	0.000531	CcSEcCtD
Degarelix—Dizziness—Epirubicin—stomach cancer	0.000465	0.000529	CcSEcCtD
Degarelix—Pruritus—Doxorubicin—stomach cancer	0.000461	0.000524	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—stomach cancer	0.000456	0.00378	CbGpPWpGaD
Degarelix—Vomiting—Epirubicin—stomach cancer	0.000448	0.000509	CcSEcCtD
Degarelix—Nausea—Methotrexate—stomach cancer	0.000447	0.000508	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—stomach cancer	0.000446	0.000507	CcSEcCtD
Degarelix—Rash—Epirubicin—stomach cancer	0.000444	0.000505	CcSEcCtD
Degarelix—Dermatitis—Epirubicin—stomach cancer	0.000443	0.000504	CcSEcCtD
Degarelix—Headache—Epirubicin—stomach cancer	0.000441	0.000501	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FST—stomach cancer	0.000439	0.00364	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ADRB2—stomach cancer	0.000436	0.00362	CbGpPWpGaD
Degarelix—Dizziness—Doxorubicin—stomach cancer	0.000431	0.00049	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—HBEGF—stomach cancer	0.000429	0.00356	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GAST—stomach cancer	0.000423	0.00351	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RGS2—stomach cancer	0.000423	0.00351	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—stomach cancer	0.000419	0.00348	CbGpPWpGaD
Degarelix—Nausea—Epirubicin—stomach cancer	0.000418	0.000475	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—stomach cancer	0.000414	0.000471	CcSEcCtD
Degarelix—Rash—Doxorubicin—stomach cancer	0.000411	0.000467	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—stomach cancer	0.00041	0.000467	CcSEcCtD
Degarelix—Headache—Doxorubicin—stomach cancer	0.000408	0.000464	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGG—stomach cancer	0.000401	0.00333	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ADRB2—stomach cancer	0.000396	0.00328	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PPP2R1A—stomach cancer	0.000388	0.00322	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—stomach cancer	0.000388	0.00322	CbGpPWpGaD
Degarelix—Nausea—Doxorubicin—stomach cancer	0.000387	0.00044	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PRKAA1—stomach cancer	0.000386	0.0032	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RBP4—stomach cancer	0.000373	0.00309	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL8—stomach cancer	0.000373	0.00309	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	0.000371	0.00308	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AGTR2—stomach cancer	0.000321	0.00266	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HSPB1—stomach cancer	0.000321	0.00266	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BMP2—stomach cancer	0.000317	0.00263	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—F2R—stomach cancer	0.000317	0.00263	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKR1C3—stomach cancer	0.000312	0.00259	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HTR1A—stomach cancer	0.000309	0.00256	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PRKCB—stomach cancer	0.000299	0.00248	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ANXA1—stomach cancer	0.000298	0.00247	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ADRB1—stomach cancer	0.000289	0.00239	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RPS6—stomach cancer	0.000276	0.00229	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PRKCB—stomach cancer	0.000271	0.00225	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6ST—stomach cancer	0.00027	0.00224	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HBEGF—stomach cancer	0.000254	0.0021	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6R—stomach cancer	0.000241	0.002	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RHOA—stomach cancer	0.00024	0.00199	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ADRB2—stomach cancer	0.000234	0.00194	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PPP2R1A—stomach cancer	0.000229	0.0019	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RHOA—stomach cancer	0.000218	0.00181	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SMAD4—stomach cancer	0.000213	0.00176	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL8—stomach cancer	0.000211	0.00175	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FYN—stomach cancer	0.000202	0.00168	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL8—stomach cancer	0.000191	0.00159	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGFR2—stomach cancer	0.00019	0.00157	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IRS2—stomach cancer	0.000174	0.00144	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CAV1—stomach cancer	0.000168	0.0014	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOA1—stomach cancer	0.000168	0.00139	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRKCB—stomach cancer	0.00016	0.00133	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6ST—stomach cancer	0.00016	0.00132	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APC—stomach cancer	0.000153	0.00127	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAPK3—stomach cancer	0.000147	0.00122	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6R—stomach cancer	0.000142	0.00118	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAPK1—stomach cancer	0.00014	0.00116	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EGFR—stomach cancer	0.00014	0.00116	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CA—stomach cancer	0.000134	0.00111	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SERPINE1—stomach cancer	0.000133	0.00111	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KRAS—stomach cancer	0.000132	0.00109	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RHOA—stomach cancer	0.000129	0.00107	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOS3—stomach cancer	0.000127	0.00106	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CA—stomach cancer	0.000121	0.00101	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ERBB2—stomach cancer	0.000119	0.000988	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL8—stomach cancer	0.000113	0.000937	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—HRAS—stomach cancer	0.000112	0.000931	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1B—stomach cancer	0.00011	0.000915	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6—stomach cancer	0.000107	0.000891	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—stomach cancer	0.000105	0.000873	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JUN—stomach cancer	0.000105	0.000871	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP9—stomach cancer	0.000102	0.000847	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1A—stomach cancer	0.000102	0.000844	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK8—stomach cancer	9.94e-05	0.000824	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—stomach cancer	9.18e-05	0.000761	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—stomach cancer	9.09e-05	0.000753	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK3—stomach cancer	8.68e-05	0.00072	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYC—stomach cancer	8.44e-05	0.0007	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK1—stomach cancer	8.26e-05	0.000685	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGFR—stomach cancer	8.26e-05	0.000685	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—stomach cancer	7.8e-05	0.000647	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CA—stomach cancer	7.17e-05	0.000594	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—stomach cancer	6.93e-05	0.000575	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRAS—stomach cancer	6.63e-05	0.00055	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6—stomach cancer	6.35e-05	0.000526	CbGpPWpGaD
